PDF(Pubmed)
Abstract：
UNASSIGNED: Tumor recurrence and pseudoprogression (PsP) have similar imaging manifestations in conventional magnetic resonance imaging (MRI), although the subsequent treatments are completely different. This study aimed to evaluate the value of perfusion-weighted imaging (PWI) in differentiating PsP from glioma recurrence.
UNASSIGNED: A comprehensive literature search was performed to evaluate clinical studies focused on differentiating recurrent glioma from PsP using PWI, including dynamic susceptibility contrast MRI (DSC-MRI), dynamic contrast enhanced MRI (DCE-MRI), and arterial spin labeling (ASL). Study selection and data extraction were independently completed by two reviewers. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was applied to evaluate the quality of the included studies. The software Stata 16.0 and Meta-Disc 1.4 were used for the meta-analysis. Meta-regression and subgroup analyses were applied to identify the sources of heterogeneity in the studies. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) prior to initiation (CRD42022304404).
UNASSIGNED: A total of 40 studies were included, including 27 English studies and 13 Chinese studies. There were 1,341 patients with glioma recurrence and 876 patients with PsP. The pooled sensitivity and specificity of DSC-MRI for differentiating glioma recurrence from PsP were 0.82 [95% confidence interval (CI): 0.78 to 0.86] and 0.87 (95% CI: 0.80 to 0.92), respectively. The pooled sensitivity and specificity of DCE-MRI were 0.83 (95% CI: 0.76 to 0.89) and 0.83 (95% CI: 0.78 to 0.87), respectively. The pooled sensitivity and specificity of ASL were 0.80 (95% CI: 0.73 to 0.86) and 0.86 (95% CI: 0.76 to 0.92), respectively.
UNASSIGNED: The DSC-MRI, DCE-MRI, and ASL perfusion techniques displayed high accuracy in distinguishing glioma recurrence from PsP, and DSC-MRI had a higher diagnostic performance than the other two techniques. However, due to the diversity of the parameters and threshold differences, further investigation and standardization are needed.
UNASSIGNED: A comprehensive literature search was performed to evaluate clinical studies focused on differentiating recurrent glioma from PsP using PWI, including dynamic susceptibility contrast MRI (DSC-MRI), dynamic contrast enhanced MRI (DCE-MRI), and arterial spin labeling (ASL). Study selection and data extraction were independently completed by two reviewers. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was applied to evaluate the quality of the included studies. The software Stata 16.0 and Meta-Disc 1.4 were used for the meta-analysis. Meta-regression and subgroup analyses were applied to identify the sources of heterogeneity in the studies. This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) prior to initiation (CRD42022304404).
UNASSIGNED: A total of 40 studies were included, including 27 English studies and 13 Chinese studies. There were 1,341 patients with glioma recurrence and 876 patients with PsP. The pooled sensitivity and specificity of DSC-MRI for differentiating glioma recurrence from PsP were 0.82 [95% confidence interval (CI): 0.78 to 0.86] and 0.87 (95% CI: 0.80 to 0.92), respectively. The pooled sensitivity and specificity of DCE-MRI were 0.83 (95% CI: 0.76 to 0.89) and 0.83 (95% CI: 0.78 to 0.87), respectively. The pooled sensitivity and specificity of ASL were 0.80 (95% CI: 0.73 to 0.86) and 0.86 (95% CI: 0.76 to 0.92), respectively.
UNASSIGNED: The DSC-MRI, DCE-MRI, and ASL perfusion techniques displayed high accuracy in distinguishing glioma recurrence from PsP, and DSC-MRI had a higher diagnostic performance than the other two techniques. However, due to the diversity of the parameters and threshold differences, further investigation and standardization are needed.
摘要：
未经证实：肿瘤复发和假性进展（PsP）在常规磁共振成像（MRI）中具有相似的影像学表现，尽管随后的治疗完全不同。本研究旨在评估灌注加权成像（PWI）在区分PsP与胶质瘤复发中的价值。
UNASSIGNED：进行了全面的文献检索，以评估使用PWI区分复发性神经胶质瘤和PsP的临床研究，包括动态磁化率对比MRI（DSC-MRI），动态对比增强MRI(DCE-MRI),和动脉自旋标记（ASL）。研究选择和数据提取由两名评审员独立完成。诊断准确性研究质量评估2（QUADAS-2）工具用于评估纳入研究的质量。采用Stata16.0软件和Meta-Disc1.4软件进行Meta分析。应用Meta回归和亚组分析来确定研究中异质性的来源。本研究在开始之前在国际前瞻性系统评价注册（PROSPERO）（CRD42022304404）中注册。
未经评估：共纳入40项研究，包括27个英语研究和13个中国研究。1,341例胶质瘤复发患者和876例PsP患者。DSC-MRI对胶质瘤复发与PsP的合并敏感性和特异性分别为0.82[95％置信区间（CI）：0.78至0.86]和0.87（95％CI：0.80至0.92），分别。DCE-MRI的合并敏感性和特异性分别为0.83（95％CI：0.76至0.89）和0.83（95％CI：0.78至0.87），分别。ASL的合并敏感性和特异性分别为0.80（95％CI：0.73至0.86）和0.86（95％CI：0.76至0.92），分别。
未经证实：DSC-MRI，DCE-MRI,ASL灌注技术在区分胶质瘤复发和PsP方面显示出很高的准确性，DSC-MRI的诊断性能高于其他两种技术。然而,由于参数和阈值差异的多样性，需要进一步调查和标准化。
UNASSIGNED：进行了全面的文献检索，以评估使用PWI区分复发性神经胶质瘤和PsP的临床研究，包括动态磁化率对比MRI（DSC-MRI），动态对比增强MRI(DCE-MRI),和动脉自旋标记（ASL）。研究选择和数据提取由两名评审员独立完成。诊断准确性研究质量评估2（QUADAS-2）工具用于评估纳入研究的质量。采用Stata16.0软件和Meta-Disc1.4软件进行Meta分析。应用Meta回归和亚组分析来确定研究中异质性的来源。本研究在开始之前在国际前瞻性系统评价注册（PROSPERO）（CRD42022304404）中注册。
未经评估：共纳入40项研究，包括27个英语研究和13个中国研究。1,341例胶质瘤复发患者和876例PsP患者。DSC-MRI对胶质瘤复发与PsP的合并敏感性和特异性分别为0.82[95％置信区间（CI）：0.78至0.86]和0.87（95％CI：0.80至0.92），分别。DCE-MRI的合并敏感性和特异性分别为0.83（95％CI：0.76至0.89）和0.83（95％CI：0.78至0.87），分别。ASL的合并敏感性和特异性分别为0.80（95％CI：0.73至0.86）和0.86（95％CI：0.76至0.92），分别。
未经证实：DSC-MRI，DCE-MRI,ASL灌注技术在区分胶质瘤复发和PsP方面显示出很高的准确性，DSC-MRI的诊断性能高于其他两种技术。然而,由于参数和阈值差异的多样性，需要进一步调查和标准化。
